Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 349-356

  Hung, Shuen Iu ^a,b   Chung, Wen Hung ^c   Liu, Zhi Sheng ^d   Chen, Chien Hsiun ^e   Hsih, Mo Song ^c   Hui, Rosaline Chung Yee ^c   Chu, Chia Yu ^d   Chen, Yuan Tsong ^a,b  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d Wuhan Children's Hospital   (China)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiepileptic drugs; Cutaneous adverse drug reactionn HLA susceptibility; Lamotrigine; Oxcarbazepine; Phenytoin; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE; HLA ANTIGEN; HLA B ANTIGEN; HLA DR ANTIGEN; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG STRUCTURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MALE; MORPHOLOGY; PATHOGENESIS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; SCHOOL CHILD; SEIZURE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; CASE-CONTROL STUDIES; CHILD; DRUG TOXICITY; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GENETIC ASSOCIATION STUDIES; HLA ANTIGENS; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; PHENYTOIN; RISK FACTORS; STEVENS-JOHNSON SYNDROME; TAIWAN; TRIAZINES; YOUNG ADULT;

EID: 77949600882     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.162     Document Type: Article

References (35)

1. Toledano R, Gil-Nagel A: Adverse effects of antiepileptic drugs. Semin. Neurol. 28(3), 317-327 (2008).
2. Kennedy GM, Lhatoo SD: CNS adverse events associated with antiepileptic drugs. CNS Drugs 22(9), 739-760 (2008).
3. Arif H, Buchsbaum R, Weintraub D et al.: Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68(20), 1701-1709 (2007).
4. Krivoy N, Taer M, Neuman MG: Antiepileptic drug-induced hypersensitivity syndrome reactions. Curr. Drug. Saf. 1(3), 289-299 (2006).
5. Roujeau JC: The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classifcation. J. Invest. Dermatol. 102(6), S28-S30 (1994).
6. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J: Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 64(7), 1134-1138 (2005).
7. Mockenhaupt M, Viboud C, Dunant A et al.: The EuroSCAR-study. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. J. Invest. Dermatol. 128(1), 35-44 (2008).
8. Nassif A, Bensussan A, Boumsell L et al.: Toxic epidermal necrolysis: effector cells are drug-specifc cytotoxic T cells. J. Allergy. Clin. Immunol. 114(5), 1209-1215 (2004).
9. Chung WH, Hung SI, Yang JY et al.: Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat. Med. 14(12), 1343-1350 (2008).
10. Chung WH, Hung SI, Hong HS et al.: Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982), 486 (2004).
11. Hung SI, Chung WH, Jee SH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4), 297-306 (2006).
12. Hung SI, Chung WH, Chen YT: HLA-B genotyping to detect carbamazepine-induced Stevens-Johnson syndrome: implications for personalizing medicine. Personalized Medicine 2(3), 225-237 (2005).
13. Lonjou C, Thomas L, Borot N et al.: RegiSCAR Group. A marker for Stevens-Johnson syndrome..: ethnicity matters. Pharmacogenomics J. 6(4), 265-268 (2006).
14. Man CB, Kwan P, Baum L et al.: Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 48(5), 1015-1018 (2007).
15. Locharernkul C, Loplumlert J, Limotai C et al.: Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
16. Knowles SR, Shapiro LE, Shear NH: Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 21(6), 489-501 (1999).
17. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr, Bazil CW: Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 71(19), 1527-1534 (2008).
18. Alvestad S, Lydersen S, Brodtkorb E: Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. Epilepsy Res. 80(2-3), 194-200 (2008).
19. Seitz CS, Pfeuffer P, Raith P, Bröcker EB, Trautmann A: Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. Ann. Allergy Asthma Immunol. 97(5), 698-702 (2006).
20. Chen YC, Chu CY, Hsiao CH: Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype. J. Eur. Acad. Dermatol. Venereol. 23(6), 702-703 (2009).
21. Pan WH, Fann CS, Wu JY et al.: Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum. Hered. 61(1), 27-30 (2006).
22. Middleton D: Current and emerging technology for HLA typing. Int. J. Hematol. 76(Suppl. 2), 150-151 (2002).
23. Tilanus MGJ, Hansen JA, Hurley CK: IHWG Technical Manual Genomic Analysis of the Human MHC, DNA-Based Typing for HLA Alleles and Linked Polymorphisms 2000. Publication of the 13th International Histocompatibility Working Group.
24. Tilanus MGJ, Hansen JH, Hurley CK (Eds). Fred Hutchinson Cancer Research Center, WA, USA, ISBN number: 0-945278-02-10 (2002).
25. Hung SI, Chung WH, Liou LB et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102(11), 4134-4139 (2005).
26. Chu CC, Lin M, Nakajima F et al.: Diversity of HLA among Taiwan's indigenous tribes and the Ivatans in the Philippines. Tissue Antigens 58(1), 9-18 (2001).
27. Haldane JB: The estimation and signifcance of the logarithm of a ratio of frequencies. Ann. Hum. Genet. 20(4), 309-311 (1956).
28. Lonjou C, Borot N, Sekula PS et al.; RegiSCAR Study Group: A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to fve high-risk drugs. Pharmacogenet. Genomics 18(2), 99-107 (2008).
29. Kazeem GR, Cox C, Aponte J et al.: High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genomics. 19(9), 661-665 (2009).
30. Kaniwa N, Saito Y, Aihara M et al.; JSAR Research Group: HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11), 1617-1622 (2008).
31. Alfrevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M: HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6), 813-818 (2006).
32. Kano Y, Hirahara K, Asano Y, Shiohara T: HLA-B allele associations with certain drugs are not confrmed in Japanese patients with severe cutaneous drug reactions. Acta Derm. Venereol. 88(6), 616-618 (2008).
33. Kashiwagi M, Aihara M, Takahashi Y et al.: Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J. Dermatol. 35(10), 683-685 (2008).
34. Lin LC, Lai PC, Yang SF, Yang RC: Oxcarbazepine-induced Stevens-Johnson syndrome: a case report. Kaohsiung J. Med. Sci. 25(2), 82-86 (2009).
35. LaRoche S, Helmers SL: The new antiepileptic drugs. JAMA 291(5), 605-614 (2004).